TY - JOUR
T1 - Single agent Talimogene Laherparepvec for stage IIIB-IVM1c melanoma patients
T2 - A systematic review and meta-analysis
AU - Stahlie, Emma H. A.
AU - Mulder, Evalyn E. A. P.
AU - Reijers, Sophie
AU - Balduzzi, Sara
AU - Zuur, Charlotte L.
AU - Klop, Willem M. C.
AU - van der Hiel, Bernies
AU - van de Wiel, Bart A.
AU - Wouters, Michel W. J. M.
AU - Schrage, Yvonne M.
AU - van Houdt, Winan J.
AU - Grunhagen, Dirk J.
AU - van Akkooi, Alexander C. J.
N1 - Funding Information: None. CZ declares research funding from Bristol Myers Squibb. MW declares a research grant received from Novartis. Winan van Houdt declares advisory board/consultancy agreement and research grant received from Amgen. AvA reports advisory board and consultancy honoraria (all paid to institute and unrelated to current work) from Amgen, Bristol- Myers Squibb, Novartis; 4SC, Merck- Pfizer, MSD- Merck, Sanofi and Sirius medical. DG declares advisory board honoraria from Amgen. All remaining authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Funding Information: CZ declares research funding from Bristol Myers Squibb. MW declares a research grant received from Novartis. Winan van Houdt declares advisory board/consultancy agreement and research grant received from Amgen. AvA reports advisory board and consultancy honoraria (all paid to institute and unrelated to current work) from Amgen, Bristol- Myers Squibb, Novartis; 4SC, Merck- Pfizer, MSD- Merck, Sanofi and Sirius medical. DG declares advisory board honoraria from Amgen. All remaining authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Publisher Copyright: © 2022 Elsevier B.V.
PY - 2022/7/1
Y1 - 2022/7/1
N2 - Single-agent Talimogene Laherparepvec (T-VEC) was developed for treatment of unresectable and injectable stage III-IV melanoma. Since its approval and reimbursement, studies have reported varying response rates. The purpose of this systematic review and meta-analysis was to investigate the efficacy and safety of T-VEC. Of 341 publications that were identified, eight studies with a total of 642 patients were included. In patients with stage IIIB-IVM1a, the pooled complete- and overall response rate (CRR and ORR) were 41% and 64%, respectively. In patients with stage IIIB-IVM1c, the pooled CRR and ORR were 30% and 44%, respectively. In patients with stage IVM1b and IVM1c, the pooled CRR and ORR were 4% and 9%, respectively. Adverse events (AEs) were seen in 41–100% of all patients and 0–11% of AEs were severe. In conclusion, single agent T-VEC achieves the highest response rates in patients with early metastatic melanoma and is well-tolerated with generally only mild toxicities.
AB - Single-agent Talimogene Laherparepvec (T-VEC) was developed for treatment of unresectable and injectable stage III-IV melanoma. Since its approval and reimbursement, studies have reported varying response rates. The purpose of this systematic review and meta-analysis was to investigate the efficacy and safety of T-VEC. Of 341 publications that were identified, eight studies with a total of 642 patients were included. In patients with stage IIIB-IVM1a, the pooled complete- and overall response rate (CRR and ORR) were 41% and 64%, respectively. In patients with stage IIIB-IVM1c, the pooled CRR and ORR were 30% and 44%, respectively. In patients with stage IVM1b and IVM1c, the pooled CRR and ORR were 4% and 9%, respectively. Adverse events (AEs) were seen in 41–100% of all patients and 0–11% of AEs were severe. In conclusion, single agent T-VEC achieves the highest response rates in patients with early metastatic melanoma and is well-tolerated with generally only mild toxicities.
KW - Immunotherapy
KW - Melanoma
KW - Metastatic
KW - T-VEC
UR - http://www.scopus.com/inward/record.url?scp=85130771298&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.critrevonc.2022.103705
DO - https://doi.org/10.1016/j.critrevonc.2022.103705
M3 - Review article
C2 - 35569723
SN - 1040-8428
VL - 175
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
M1 - 103705
ER -